Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Follow-On AGs Gaining Ground with 10 Launches in 2 Years, More Expected amid Generic Quality Concerns
September 9, 2021
- Aloxi Authorized Generic Now Available Ahead of Gx Contenders
September 8, 2021
- MSD Leading in Oral COVID-19 Drug Race in Japan, Trailed by Pfizer; Shionogi Top Domestic Player
September 8, 2021
- Post-Vaccination Death Cases Being Investigated with Integrity: Takeda
September 8, 2021
- Japan Ethical Drug Sales Down 0.5% in July: Crecon
September 8, 2021
- Nichi-Iko’s Medipal Tie-Up Stirring Concerns over Generic Trades, Price Gyrations
September 7, 2021
- Keytruda Top-Selling Drug in Japan in August: Encise
September 7, 2021
- Takeda Faces New Problem on Leuplin, System Glitch Cripples Supply of 1, 3-Month Products
September 7, 2021
- GSK Files COVID-19 Antibody Drug Sotrovimab in Japan
September 7, 2021
- Roche Diagnostics Launches EZH2 Mutations Test for Eisai’s Tazverik in Japan
September 7, 2021
- CureApp Files Therapeutic App for Hypertension in Japan, Eyes Launch in 2022
September 6, 2021
- Sunovion Grants European Rights for Kynmobi to BIAL
September 6, 2021
- Takeda Grabs Approval for Zejula Tablet Form
September 6, 2021
- Japan Pharma Officials Relieved by Exit of Suga, Hardliner on Industry
September 6, 2021
- Medipal Now Biggest Shareholder of Nichi-Iko
September 6, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Kissei Grants China Rights for Linzagolix to Bio Genuine
September 3, 2021
- Sumitomo Dainippon to Open Office in Vietnam
September 3, 2021
- Viatris Takes Over 14 Off-Patent Drugs, 4 AGs from Pfizer
September 3, 2021
- Reed Maurer, First Japan Representative for PhRMA, Dies at 83
September 3, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…